TPTE and melanoma: BioNTech developed a cancer mRNA vaccine, called FixVac (BNT 111), targeting simultaneously four melanoma TAAs, including New York esophageal squamous cell carcinoma 1 (NY-ESO-1), melanoma-associated antigen A3 (MAGE-A3), tyrosinase, and transmembrane phosphatase with tensin homology (TPTE) (163).